Corbus Pharmaceuticals AI Stock Analysis
Corbus Pharmaceuticals (3371) AI Stock Analysis
Corbus Pharmaceuticals
(Frankfurt:3371)
No summary available
Corbus Pharmaceuticals (3371) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 56.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 233
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.95
- Revenue Growth
- ―
- EPS Growth
- -6.00%
- Country
- Germany
- Employees
- 36
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Corbus Pharmaceuticals Business Overview & Revenue Model
Company Description
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression...
Corbus Pharmaceuticals Risk Analysis
Corbus Pharmaceuticals disclosed 51 risk factors in its most recent earnings report. Corbus Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCorbus Pharmaceuticals Peers Comparison
Overall Rating
IPHA50Neutral
GOSS47Neutral
EQ43Neutral
ALDX41Neutral
IMUX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $121.06M | -1.94 | 152.56% | ― | -24.21% | 1.17% | |
| 47Neutral | $69.91M | -0.32 | 99.85% | ― | 78.03% | 34.96% | |
| 43Neutral | $90.56M | -6.24 | -37.33% | ― | -100.00% | 71.65% | |
| 41Neutral | $41.88M | -2.10 | >-0.01% | ― | ― | 56.04% | |
| 40Underperform | $119.42M | -1.68 | -136.26% | ― | ― | 48.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:3371 | Corbus Pharmaceuticals Holdings | 2.75 | -6.80 | -71.16% | |
| IMUX | Immunic, Inc. | 7.52 | 0.64 | 9.38% | |
| ALDX | Aldeyra Therapeutics | 0.67 | -4.06 | -85.81% | |
| EQ | Equillium | 1.10 | 0.09 | 8.91% | |
| GOSS | Gossamer Bio | 11.43 | -237.37 | -95.41% | |
| IPHA | Innate Pharma SA Sponsored ADR | 1.03 | -0.79 | -43.41% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
